Guided Therapeutics Inc

Guided Therapeutics Inc. develops and commercializes the LuViva Advanced Cervical Scan, an electromedical device used for cervical cancer screening. The company’s business is centered on selling LuViva instruments and disposables through direct and distribution channels, while it continues to pursue regulatory approvals needed to expand commercial adoption.

−308,0 %

74,4 %

−416,7 %

+10 857,1 %

0.09

0.02

— Guided Therapeutics Inc
%
LuViva devices70% Cervical cancer screening instruments sold as instrumentation packages to hospitals, clinics, and partners.
Disposables and consumables30% RFID chips and related consumable components used with LuViva systems.

The company sells primarily to medical distributors, healthcare systems, hospitals, and clinics that use LuViva for...

  • Medical distributorsprimary

    Buy LuViva systems for resale and market development in approved territories.

  • Hospitals and clinicsprimary

    Purchase devices for cervical cancer screening programs and patient throughput.

  • Government health ministriessecondary

    Evaluate LuViva for public screening programs where scale and cost matter.

  • Government hospital systemssecondary

    Buy devices for regional deployment, such as the Sulawesi hospital system in Indonesia.

Guided Therapeutics is still a small-revenue company, but its commercial focus spans the United States, China, and...

  • •United States is a core market and the FDA approval path remains critical
  • •China is strategically important but depends on NMPA approval
  • •Europe includes approved markets such as Poland, Hungary, Romania, and Russia
  • •Turkey is being pursued through the Ministry of Health and clinical study work
  • •Indonesia has already generated orders and is a near-term fulfillment market

The company’s near-term strategy is to secure regulatory approvals, convert distributor relationships into shipments,...

01
Regulatory approvals in the U.S. and Chinashort-term

Commercial scale depends on FDA and NMPA clearance, especially for the largest target markets.

02
Distributor-led international expansionmedium-term

The company lacks a large direct sales infrastructure, so partners are essential for market access.

03
Cash preservation and external fundingshort-term

The business remains loss-making and needs capital to continue operations and commercialization.

Guided Therapeutics faces substantial regulatory, funding, and commercialization risk because its revenue base is still...

critical

Going concern / financing risk

The company has recurring losses and needs additional capital to continue operations and fund studies.

Scope
Operations, clinical work, manufacturing readiness
Materiality
high
high

Regulatory approval delays

Sales depend on FDA and NMPA clearance, and delays directly push out revenue and cash generation.

Scope
LuViva commercialization in the U.S. and China
Materiality
high
high

Distributor and counterparty risk

Sales depend on partners such as SMI, Newmars, and HDMT, and one partner is in contractual default.

Scope
Order conversion, collections, market access
Materiality
high
high

Market acceptance risk

The product must gain clinical and commercial acceptance versus existing cervical screening methods.

Scope
Adoption by hospitals, clinics, and public health systems
Materiality
high
medium

Geopolitical and country-specific market risk

Russia and other markets may face approval, trade, or operating constraints.

Scope
European distribution and international expansion
Materiality
medium
Revenue recognition timing
Can shift revenue between quarters and affect comparability
Deferred revenue
Indicates revenue already billed or collected but not yet recognized
Inventory valuation
Can affect gross margin and operating results
Fair value of equity instruments
Can create non-cash expense volatility

Grace Therapeutics, Inc.

GRCE · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Definium Therapeutics, Inc.

DFTX · Medicinal Chemicals & Botanical Products

TherapeuticsMD, Inc.

TXMD · Pharmaceutical Preparations

Perspective Therapeutics, Inc.

CATX · Pharmaceutical Preparations

Century Therapeutics, Inc.

IPSC · Biological Products, (No Diagnostic Substances)

: 28.4.2026